Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 780 Brannan Street SAN FRANCISCO CA 94103 |
Tel: | N/A |
Website: | https://olema.com |
IR: | See website |
Key People | ||
Sean P. Bohen President, Chief Executive Officer, Director | Shane Kovacs Chief Operating and Financial Officer | John B. Moriarty Executive Vice President, Chief Legal Officer and Secretary |
David C. Myles Chief Discovery and Non-Clinical Development Officer | Naseem Zojwalla Chief Medical Officer |
Business Overview |
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The Company's OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including ESR1 and PIK3CA mutations and central nervous system (CNS), metastasis. It is in the Phase I/ II clinical trial, and in Phase Ib/ II combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. |
Financial Overview |
For the fiscal year ended 31 December 2023, Olema Pharmaceuticals Inc revenues was not reported. Net loss decreased 8% to $96.7M. Lower net loss reflects Interest income increase from $2.2M to $8.3M (income), General and administrative - Balancing decrease of 27% to $13.3M (expense), Stock-based Compensation in SGA decrease of 14% to $5.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.62 to -$2.14. |
Employees: | 74 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $290.07M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$104.58M as of Dec 31, 2023 |
Net annual income (TTM): | -$96.66M as of Dec 31, 2023 |
Free cash flow (TTM): | -$83.73M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 55,914,741 as of Mar 7, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |